Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 239

The DOI matches its Crossref record.

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

Open access
Mease, Philip J, Lertratanakul, Apinya, Anderson, Jaclyn K, Papp, Kim, Van den Bosch, Filip, Tsuji, Shigeyoshi, Dokoupilova, Eva, Keiserman, Mauro, Wang, Xin, Zhong, Sheng, McCaskill, Reva M, Zueger, Patrick, Pangan, Aileen L, Tillett, William · 2021 · Annals of the Rheumatic Diseases

Abstract

BACKGROUND: Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD). METHODS: In this 24-week randomised, placebo-controlled, double-blind, phase 3 trial, 642 patients were randomised (2:2:1:1) to once per day upadacitinib 15 mg or 30 mg, placebo followed by upadacitinib 15 mg or placebo followed by upadacitinib 30 mg at week 24. The primary endpoint was the proportion of patients achieving American College of Rheumatology (ACR) 20 response at week 12. Achievement of minimal disease activity (MDA) was assessed at week 24. Treatment-emergent adverse events are reported for all patients who received at least one dose of trial drug. RESULTS: At week 12, significantly more patients receiving upadacitinib 15 mg and 30 mg versus placebo achieved ACR20 (56.9% and 63.8% vs 24.1%; p<0.001 for both comparisons). At week 24, MDA was achieved by more upadacitinib 15 mg-treated (25.1%) and 30 mg-treated patients (28.9%) versus placebo (2.8%; p<0.001 for both comparisons). Generally, the rates of treatment-emergent adverse events were similar with placebo and upadacitinib 15 mg and higher with upadacitinib 30 mg at week 24. Rates of serious infections were 0.5%, 0.5% and 2.8% with placebo, upadacitinib 15 mg and upadacitinib 30 mg, respectively. CONCLUSION: In this trial of patients with active PsA who had inadequate response or intolerance to at least one biologic DMARD, upadacitinib 15 mg and 30 mg was more effective than placebo over 24 weeks in improving signs and symptoms of PsA. CLINICAL TRIAL REGISTRATION NUMBER: NCT03104374.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2020-218870

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 239

Metadata

Authors
Mease, P. J., Lertratanakul, A., Anderson, J. K., Papp, K., Van den Bosch, F., Tsuji, S., Dokoupilova, E., Keiserman, M., Wang, X., Zhong, S., McCaskill, R. M., Zueger, P., Pangan, A. L., & Tillett, W.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2021-03
Volume
80
Issue
3
Pages
312-320
ISSN
0003-4967 (ISSN-L)
OpenAlex
W3109739095
Cited by
239
References
0
FWCI
23.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. https://app.cochat.ai/papers/10.1136/annrheumdis-2020-218870
The paper
Mease, P. J., Lertratanakul, A., Anderson, J. K., Papp, K., Van den Bosch, F., Tsuji, S., Dokoupilova, E., Keiserman, M., Wang, X., Zhong, S., McCaskill, R. M., Zueger, P., Pangan, A. L., & Tillett, W. (2021). Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2020-218870

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.